About Us
Cognosetta is a drug discovery company headquartered in Tampa, Florida. Founded in 2018, the company is focused on discovering therapeutic drugs for treating nervous system disorders.
At Cognosetta, we discover and develop ion channel and neuroreceptor modulators for therapeutic applications. Our mission is to advance innovative pharmacological solutions for tinnitus and other hearing disorders that currently lack FDA-approved medications. Cognosetta is founded on a combination of biological and clinical expertise, powerful small molecule and peptide ion channel modulators, proprietary preclinical methodology, and the determination to improve lives.
Our Leadership Team
Luisa Scott, PhD
Chief Scientific Officer and President
Dr. Scott is the Chief Scientific Officer and founder of Cognosetta. She is an expert in ion channel physiology, from altering and recording individual ion channels, to understanding how ion channels shape circuit function and behavior. She has designed biological drug discovery platforms based on high-throughput binding and phenotypic screens. As a neuroscientist, she then applied selected drug candidates to solve problems with hearing, alcohol addiction, and neurodegenerative diseases. Dr. Scott and Dr. Walton co-discovered a class of peptides that improve auditory function in hearing disorders. At Cognosetta, she is focused on fostering the validation of ion channels as targets for neurological diseases, and then discovering and developing novel therapeutic leads based on these targets.
Joseph Walton, PhD, CCC-A
Vice President, Audiology
Dr. Walton is the Vice President of Audiology and co-founder of Cognosetta. Dr. Walton is an expert in assessing hearing and auditory system function in humans and animals models. He has conducted over 20 years of research assessing peripheral and central auditory system function in mouse models of hearing disorders. He has used these models to study experimental interventions and develop objective assays of auditory function. Dr. Scott and Dr. Walton co-discovered a class of peptides that improve auditory function in mouse models of hearing disorders. Dr. Walton's broad background as an audiologist and scientist studying animal models of human disease will advance the development of drug candidates at Cognosetta that translate into effective human medications.
.jpg)
Michelle Bayly, PhD
Director of Medical Affairs
Dr. Bayly is the Director of Medical Affairs at Cognosetta. An accomplished neuroscientist, Dr. Bayly brings with her with over 10 years of experience in leading and managing preclinical and clinical R&D projects aimed at the identification of novel targets and therapeutic drugs for CNS, nephrology, and cardiovascular diseases.
As an experienced presenter, educator and science communicator, she's adept at making complex scientific information accessible to a wide range of audiences.
General
Announcements, events and press releases
Science Media
Read about our scientific publications and presentations
